rs34714364 — APH1A APH1A gamma-secretase variant

APH1A Gamma-Secretase Variant — Where Chronotype Meets Alzheimer's Biology

Near the APH1A gene on chromosome 1, a synonymous variant in the adjacent CA14 gene tags regulatory differences at one of the most unexpected intersections in human genetics: the overlap between when you naturally prefer to wake up and how your brain processes the amyloid precursor protein (APP). APH1A¹¹ APH1A
anterior pharynx-defective 1A, a seven-transmembrane scaffolding subunit of the gamma-secretase complex encodes a required component of the enzyme that cleaves APP into fragments including the neurotoxic Aβ42 peptide — the primary driver of amyloid plaque formation in Alzheimer's disease. The rs34714364-T allele at the APH1A/CA14 locus is one of the genetic signals for morningness — the tendency to prefer early wake times and morning activity²² morningness — the tendency to prefer early wake times and morning activity
circadian chronotype; the genetically determined phase of the sleep-wake cycle that varies by roughly 2 hours across the population.

The Mechanism

rs34714364 sits in the coding sequence of CA14 (carbonic anhydrase 14) as a synonymous G>T change that does not alter the protein sequence. Its functional significance likely arises from its position approximately 3 kb from the APH1A transcription start site, where it may tag regulatory haplotypes that modulate APH1A expression. APH1A promoter variation is known to alter gamma-secretase output³³ APH1A promoter variation is known to alter gamma-secretase output
the -980C/G promoter polymorphism (rs3754048) increases YY1-driven APH1A transcription 2.7-fold, elevating γ-secretase activity and Aβ42 production. The pathway connecting this locus to chronotype is not fully resolved, but two mechanisms are plausible: first, APP cleavage products — particularly the APP intracellular domain (AICD) — have been shown to modulate transcription of core clock genes; second, gamma-secretase cleaves Notch receptors whose downstream signaling feeds into the circadian timing system in the retina and hypothalamus, tissues identified as particularly enriched for chronotype-associated expression in the Jones 2019 GWAS. The variant's effect on sleep timing is modest but population-wide, and the biological connection to APP biology creates a plausible, if not yet fully mechanistically resolved, pathway from chronotype genetics to Alzheimer's sleep pathology.

The Evidence

The chronotype signal at this locus was first identified by Hu et al. 2016⁴⁴ Hu et al. 2016
Hu Y et al. GWAS of 89,283 individuals identifies genetic variants associated with self-reporting of being a morning person. Nat Commun. 2016 in a GWAS of 89,283 individuals. The T allele carried an odds ratio of 1.12 (95% CI 1.08–1.16, p=2×10⁻¹⁰) for self-reported morningness — a modest but highly significant effect. This was replicated in the landmark Jones et al. 2019⁵⁵ Jones et al. 2019
Jones SE et al. Genome-wide association analyses of chronotype in 697,828 individuals provides insights into circadian rhythms. Nat Commun. 2019 study, which expanded the known chronotype loci to 351 across 697,828 participants from UK Biobank and 23andMe. Mendelian randomization in that study showed that morning preference causally associates with better mental health outcomes. Notably, Emmanuel and von Schantz 2018⁶⁶ Emmanuel and von Schantz 2018
Emmanuel P, von Schantz M. Absence of morningness alleles in non-European populations. Chronobiol Int. 2018 found that the morningness allele at the APH1A/CA14 locus is essentially absent in East Asian populations (T allele frequency <0.1%), highlighting the ancestry-specific nature of this circadian genetic signal.

The connection to Alzheimer's biology deepens the clinical significance beyond chronotype alone. Lim et al. 2014⁷⁷ Lim et al. 2014
Lim MM et al. The sleep-wake cycle and Alzheimer's disease: what do we know? Neurodegener Dis Manag. 2014 established that amyloid-beta accumulation and sleep-wake fragmentation form a positive feedback loop: rising Aβ burden disrupts sleep architecture, and disrupted sleep reduces glymphatic clearance of Aβ, further accelerating plaque deposition. Wu et al. 2019⁸⁸ Wu et al. 2019
Wu H et al. The role of sleep deprivation and circadian rhythm disruption as risk factors of Alzheimer's disease. Front Neuroendocrinol. 2019 confirmed that circadian disruption impairs the glymphatic clearance system and reduces melatonin, raising oxidative stress in neurons. Variants near APH1A that influence both chronotype (and thus sleep quality) and potentially gamma-secretase activity thus sit at the intersection of two complementary Alzheimer's risk pathways.

Practical Actions

For TT carriers (approximately 2% of Europeans), the genetic profile suggests a naturally earlier chronotype and, given the APH1A locus biology, an additional rationale to protect sleep timing and quality. For GT heterozygotes (~26%), a mild morningness tendency is present. The evidence supports protecting circadian rhythm alignment as the primary modifiable lever — specifically, maintaining consistent light exposure patterns that reinforce the natural morning preference this genotype already confers, and monitoring for early signs of sleep fragmentation (a known early marker of Alzheimer's pathology) as part of long-term brain health strategy.

Interactions

The APH1A/CA14 locus acts in parallel with other circadian-clock variants already in the GeneOps database. rs1801260 (CLOCK gene 3111T/C) and rs35333999 (TIMELESS) both influence circadian period length and interact with sleep quality phenotypes. rs3754048 is the functional APH1A promoter variant with documented effects on gamma-secretase activity and Alzheimer's risk — it is the upstream regulatory variant whose expression effects may be tagged by rs34714364 at the population level. Future compound action analysis should consider the combined profile of rs34714364-TT with APH1A promoter variants and CLOCK variants for a more complete circadian/Alzheimer's risk picture.